These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

92 related items for PubMed ID: 11498368

  • 1. Molecular targets and cancer therapeutics: discovery, development and clinical validation.
    Teicher BA.
    Drug Resist Updat; 2000 Apr; 3(2):67-73. PubMed ID: 11498368
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. The opportunities and challenges of personalized genome-based molecular therapies for cancer: targets, technologies, and molecular chaperones.
    Workman P.
    Cancer Chemother Pharmacol; 2003 Jul; 52 Suppl 1():S45-56. PubMed ID: 12819933
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Molecular targets and cancer therapeutics: discovery, development & clinical validation--AACR-NCI-EORTC international conference.
    Orr RM.
    IDrugs; 2000 Feb; 3(2):167-9. PubMed ID: 16107931
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Taking advantage of tumor cell adaptations to hypoxia for developing new tumor markers and treatment strategies.
    Ebbesen P, Pettersen EO, Gorr TA, Jobst G, Williams K, Kieninger J, Wenger RH, Pastorekova S, Dubois L, Lambin P, Wouters BG, Van Den Beucken T, Supuran CT, Poellinger L, Ratcliffe P, Kanopka A, Görlach A, Gasmann M, Harris AL, Maxwell P, Scozzafava A.
    J Enzyme Inhib Med Chem; 2009 Apr; 24 Suppl 1():1-39. PubMed ID: 19330638
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Cancer research 2000: drug resistance, new targets and drugs in development.
    Broxterman HJ, Georgopapadakou N.
    Drug Resist Updat; 2000 Jun; 3(3):133-138. PubMed ID: 11498376
    [Abstract] [Full Text] [Related]

  • 13. Energy balance, physical activity, and cancer risk.
    Fair AM, Montgomery K.
    Methods Mol Biol; 2009 Jun; 472():57-88. PubMed ID: 19107429
    [Abstract] [Full Text] [Related]

  • 14. Cancer vaccines: an update with special focus on ganglioside antigens.
    Bitton RJ, Guthmann MD, Gabri MR, Carnero AJ, Alonso DF, Fainboim L, Gomez DE.
    Oncol Rep; 2002 Jun; 9(2):267-76. PubMed ID: 11836591
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. New drugs for the treatment of advanced-stage diffuse large cell lymphomas.
    O'Connor OA, Hamlin P.
    Semin Hematol; 2006 Oct; 43(4):251-61. PubMed ID: 17027659
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Integration of Translational Research in the European Organization for Research and Treatment of Cancer Research (EORTC) Clinical Trial Cooperative Group Mechanisms.
    Lehmann F, Lacombe D, Therasse P, Eggermont AM.
    J Transl Med; 2003 Aug 07; 1(1):2. PubMed ID: 14527343
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.